Date clarification: IDEX’s scheduled 2026Q2 earnings call is today, Wednesday, July 29, 2026—not tomorrow. The prior close was $224.69 on July 28.
IDEX enters the second quarter with a favorable setup: management raised 2026 guidance after a strong 1Q, HST backlog and orders were robust, and the company has increasingly positioned its portfolio toward AI/data-center infrastructure, semiconductor, space & defense, and water-related applications. The central question for investors is whether those durable growth platforms can continue to offset still-uneven short-cycle industrial demand in FMT and project timing in FSDP—while maintaining the margin framework embedded in the full-year outlook.
The quarter’s headline hurdle is well defined. At 1Q earnings, IDEX guided to 2Q organic sales growth of 3%–4%, adjusted EBITDA margin of 26.5%–27.0%, and adjusted EPS of $2.07–$2.12. The midpoint EPS guide of $2.095 implies roughly 1% year-over-year growth versus 2Q25 adjusted EPS of $2.07. That makes the earnings bar manageable; the more consequential driver of the stock is likely to be commentary on the second half and whether the raised full-year targets still look conservative.
Health & Science Technologies is the key swing factor. In 1Q, HST organic sales grew 11% and organic orders grew 17%, supported by data-center power, semiconductor, optical switching, space & defense, and pharma demand. Management described the associated backlog as providing increased visibility through the balance of 2026 and into 2027.
For 2Q, investors should look for:
The important nuance is margins. HST’s 1Q adjusted EBITDA margin expanded 100 bps year over year to 26.6%, but management has said recently acquired businesses—including Mott, Muon, and Micro-LAM—remain below segment-average profitability. Investors will want confirmation that 8020 actions and mix improvement can lift incremental margins toward management’s longer-term aspiration.
FMT posted 2% organic sales growth in 1Q, despite 9% organic order growth. Water, mining, semiconductor-related high-purity water, and pumps were constructive; chemical and general industrial demand remained weaker.
This makes FMT particularly important in 2Q:
In short, HST is expected to perform. FMT determines whether IDEX is merely meeting its raised plan or building a case for another upward revision.
Fire & Safety/Diversified Products declined 1% organically in 1Q. Strong North American fire-and-rescue demand was offset by lower dispensing volumes due to project timing. Management expected dispensing to stabilize sequentially.
The relevant 2Q read-throughs are:
A stabilization in FSDP would remove a potential drag from the 2026 outlook, even if growth remains modest.
| Metric | 2Q25 actual | 2Q26 company outlook | What matters |
|---|---|---|---|
| Organic sales growth | 1% | 3%–4% | Delivery against the raised growth plan |
| Adjusted EPS | $2.07 | $2.07–$2.12 | Beat/raise potential and full-year EPS confidence |
| Adjusted EBITDA margin | 27.4% | 26.5%–27.0% | Mix, productivity, and acquired-business margins |
| HST organic sales | 4% | High-single-digit growth implied for FY26 | Durability of secular growth and backlog conversion |
| FMT organic sales | -2% | Roughly flat FY26 outlook | Water strength versus industrial/chemical softness |
| FSDP organic sales | 2% | Roughly flat FY26 outlook | Fire & Safety demand and dispensing normalization |
The reported-sales comparison may look stronger than organic growth because of acquisitions and foreign exchange, but investors should focus on organic growth, segment mix, EBITDA margin, and orders/backlog.
After 1Q, IDEX raised its full-year 2026 outlook to:
The guidance increase was attributed principally to company-specific growth investments and HST momentum—not a broad industrial-cycle recovery. That distinction matters. It suggests IDEX does not need a macro inflection to meet its plan, but it also means the upside case depends on execution in its targeted platforms rather than a rising tide across all businesses.
Bullish outcome: IDEX meets or exceeds the 2Q EPS and growth framework, reiterates or raises full-year guidance, reports sustained HST order strength, and speaks more positively about FMT industrial trends.
Neutral outcome: IDEX delivers within its 2Q ranges, reiterates 2026 guidance, and maintains a cautious view on FMT/FSDP while HST remains strong.
Bearish outcome: HST growth or orders slow materially, acquired-business margin improvement disappoints, FMT weakness broadens beyond chemicals/general industrial, or tariff and price/cost uncertainty causes a more cautious second-half view.
IDEX has demonstrated solid execution: 1Q adjusted EBITDA margin increased 50 bps to 26.0%, even as gross margin declined 40 bps on unfavorable mix and price/cost pressure. For 2Q, the most useful margin indicators will be:
Cash conversion also deserves attention. 1Q free cash flow was $86 million, down modestly year over year because of working-capital investment and higher capital expenditures. Management considers the first quarter seasonally weak and still expects at least 100% full-year free-cash-flow conversion. A sharp 2Q cash-flow recovery would reinforce confidence in that target.
Capital deployment is supportive: IDEX repurchased $76 million of stock in 1Q and expects to sustain approximately that quarterly pace through 2026, alongside dividends and bolt-on M&A. Gross leverage stood at roughly 2x at the end of 1Q, leaving flexibility for tuck-in acquisitions.
IEX closed at $224.69 on July 28, up approximately 25.5% from its January 2 close of $179.06. Based on the midpoint of full-year adjusted EPS guidance ($8.45), the shares trade at roughly 26.6x that earnings measure.
That premium valuation increases the importance of qualitative proof points: sustained HST growth, credible margin expansion in acquired platforms, and evidence that FMT’s encouraging orders are becoming revenue. The stock has already recovered from the immediate post-1Q reaction, so simply reporting an in-line quarter may not be enough to drive a material re-rating.
IDEX’s 2Q report is primarily a test of follow-through on a strong 1Q rather than a rescue quarter. The company has a credible secular-growth narrative and a favorable internal setup through HST, but the market will look for confirmation that the strength is broadening—particularly in FMT—and that margins in acquired platforms are improving as revenue scales.
A clean result would feature 3%–4% or better organic growth, adjusted EPS at or above the top end of guidance, durable HST backlog commentary, stable-to-improving FMT trends, and preserved or higher full-year guidance. The key risk is that a premium valuation leaves little room for any evidence that HST momentum, industrial demand, or margins are fading.